CD19 and Miyoshi myopathy: Clinical trials have explored the use of second-generation CAR T-cells targeting BCMA (4-1BB-EGFRt) (NCT03070327, NCT03093168, NCT03502577), as well as third-generation CAR T-cells targeting both BCMA and CD19 (OX40/CD28-EGFRt) (NCT03455972), in MM patients.